Development of an enzyme‑linked immunosorbent assay for camptothecin.
Animals
Antibodies, Monoclonal
/ biosynthesis
Binding, Competitive
Camptothecin
/ analogs & derivatives
Cross Reactions
Enzyme-Linked Immunosorbent Assay
/ methods
Female
Haptens
/ chemistry
Hemocyanins
/ chemistry
Humans
Immune Sera
/ chemistry
Limit of Detection
Mice
Mice, Inbred BALB C
Protein Binding
Topotecan
/ analysis
Journal
Molecular medicine reports
ISSN: 1791-3004
Titre abrégé: Mol Med Rep
Pays: Greece
ID NLM: 101475259
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
08
11
2018
accepted:
10
05
2019
pubmed:
8
6
2019
medline:
18
12
2019
entrez:
8
6
2019
Statut:
ppublish
Résumé
The use of camptothecin and its analogues has increased in clinical settings and in agriculture. Therefore, camptothecins and their derivatives, metabolites and degradation products are frequently found in the environment. Therefore, it is important to develop an ELISA for the quantification of camptothecins in human plasma, plants, animal tissues and other matrices. The present study developed a novel competitive indirect ELISA for camptothecin using a monoclonal antibody (MAb). In total, two haptens and various carrier proteins were tested to select the most suitable immunogen for the production of MAbs against camptothecin. Hapten 1 conjugated with keyhole limpet hemocyanin was selected for the preparation of MAb 5A3, and was used to establish a competitive indirect ELISA for camptothecin. A total of three derivatives of camptothecin used in clinical practice were examined. Topotecan showed an IC50 value of 0.68 µg/ml with a detection limit of 0.19 µg/ml, belotecan showed an IC50 value of 0.87 µg/ml with a detection limit of 0.22 µg/ml and irinotecan showed an IC50 value of 2.85 µg/ml with a detection limit of 0.47 µg/ml. The cross‑reactivity results suggested that the assay developed in the present study possessed a high sensitivity to camptothecin. Therefore, this immunoassay technique may be suitable for monitoring the levels of camptothecin in compound analysis, clinical applications, and analyses of food and environmental samples.
Identifiants
pubmed: 31173229
doi: 10.3892/mmr.2019.10342
pmc: PMC6625201
doi:
Substances chimiques
Antibodies, Monoclonal
0
Haptens
0
Immune Sera
0
belotecan
27Z82M2G1N
Topotecan
7M7YKX2N15
Hemocyanins
9013-72-3
keyhole-limpet hemocyanin
FV4Y0JO2CX
Camptothecin
XT3Z54Z28A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
959-966Références
Mol Pharmacol. 2000 Feb;57(2):243-51
pubmed: 10648633
Bioconjug Chem. 2004 Nov-Dec;15(6):1264-74
pubmed: 15546192
Nat Prod Res. 2005 Jun;19(4):393-412
pubmed: 15938148
Cancer Res. 1991 Aug 15;51(16):4187-91
pubmed: 1651156
Nat Rev Cancer. 2006 Oct;6(10):789-802
pubmed: 16990856
Chem Pharm Bull (Tokyo). 1991 Oct;39(10):2574-80
pubmed: 1806276
Anal Chim Acta. 2008 May 19;615(2):174-83
pubmed: 18442523
J Med Chem. 1991 Jan;34(1):98-107
pubmed: 1846923
J Med Chem. 2009 Feb 26;52(4):1029-39
pubmed: 19530720
Int Immunopharmacol. 2009 Nov;9(12):1452-9
pubmed: 19747570
Nat Prod Res. 2010 Apr;24(6):509-14
pubmed: 20397103
J Econ Entomol. 2010 Apr;103(2):492-6
pubmed: 20429466
Methods. 2012 Feb;56(2):136-44
pubmed: 22178691
J Immunol Methods. 2013 Feb 28;388(1-2):60-7
pubmed: 23234756
Analyst. 2013 Feb 21;138(4):981-90
pubmed: 23304696
Eur J Med Chem. 2013 May;63:746-57
pubmed: 23578545
J Immunol Methods. 1989 Jun 2;120(1):133-43
pubmed: 2499636
J Med Chem. 2014 Jul 24;57(14):6008-18
pubmed: 25003995
Med Res Rev. 2015 Jul;35(4):753-89
pubmed: 25808858
Acta Ophthalmol. 2016 Aug;94(5):471-8
pubmed: 26893290
J Exp Clin Cancer Res. 2016 Mar 31;35:56
pubmed: 27029323
J Immunol. 2018 Jun 15;200(12):3981-3992
pubmed: 29735481
J Biol Chem. 1985 Nov 25;260(27):14873-8
pubmed: 2997227
Analyst. 2018 Aug 20;143(17):4057-4066
pubmed: 30059081
J Immunol Methods. 1986 Aug 21;92(1):15-20
pubmed: 3528298
Gan. 1976 Oct;67(5):693-701
pubmed: 828116
J Med Chem. 1998 Jan 1;41(1):31-7
pubmed: 9438019
Biochem Pharmacol. 1998 Mar 1;55(5):709-11
pubmed: 9515582
Arch Pharm Res. 1998 Oct;21(5):581-90
pubmed: 9875499